News
Sarepta Therapeutics Stock Plunges After Another Patient Death Is Linked to One of Its Gene Therapies
One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to the death of a 51-year-old man last month who received the treatment in a clinical trial.
Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...
4d
Sarepta Therapeutics stock sinks further Tuesday after halting shipment of bestselling drug Elevidys
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Sarepta Therapeutics' (SRPT) stock has been hammered in the past week after the company was forced to pause shipments of its top-selling Duchenne muscular dystrophy (DMD) therapy Elevidys — throwing ...
Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback